{"id":"faster-aspart","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1201496","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Faster aspart is a modified version of insulin aspart designed with excipients (niacinamide) that accelerate its absorption and onset of action compared to standard insulin aspart. It mimics the body's natural rapid postprandial insulin response by quickly lowering blood glucose levels after meals. The drug works by binding to insulin receptors on muscle and fat cells, promoting glucose uptake and storage while suppressing hepatic glucose production.","oneSentence":"Faster aspart is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:12.569Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04149262","phase":"","title":"Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2019-11-15","conditions":"Type 1 Diabetes","enrollment":44},{"nctId":"NCT04698018","phase":"PHASE1","title":"A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-20","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":23},{"nctId":"NCT04588259","phase":"PHASE3","title":"Research Study to Compare a New Medicine \"Fast-acting Insulin Aspart\" to Another Medicine \"Insulin Aspart\" in Chinese People With Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-09","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":331},{"nctId":"NCT04381429","phase":"PHASE4","title":"Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-08-17","conditions":"Cystic Fibrosis-related Diabetes","enrollment":38},{"nctId":"NCT03987802","phase":"","title":"An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-01-20","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":42},{"nctId":"NCT05262595","phase":"PHASE1","title":"A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-03-03","conditions":"Diabetes Mellitus, Type 1","enrollment":19},{"nctId":"NCT03659799","phase":"PHASE4","title":"Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2019-04-12","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT03770767","phase":"PHASE3","title":"Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2019-11-11","conditions":"Diabetes Mellitus, Pregnancy Complications","enrollment":216},{"nctId":"NCT04759144","phase":"NA","title":"FASter Insulin in Closed-loop Technology in Children","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2021-03-12","conditions":"Type 1 Diabetes Mellitus","enrollment":27},{"nctId":"NCT04655690","phase":"PHASE1","title":"A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-09","conditions":"Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT03579615","phase":"NA","title":"Comparison of Day and Night Closed-loop With Faster-acting Insulin Aspart With Insulin Aspart","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2020-12-23","conditions":"Diabetes Mellitus, Type 1","enrollment":18},{"nctId":"NCT03268005","phase":"PHASE3","title":"Research Study Comparing a New Medicine \"Fast-acting Insulin Aspart\" to Another Already Available Medicine \"NovoRapid\"/\"NovoLog\" in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-09-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1264},{"nctId":"NCT04853030","phase":"NA","title":"Fast Advanced Closed-Loop Therapy","status":"COMPLETED","sponsor":"University of Ljubljana, Faculty of Medicine","startDate":"2021-04-06","conditions":"Type 1 Diabetes","enrollment":30},{"nctId":"NCT04772729","phase":"PHASE4","title":"Does the Use of Fiasp vs. Asp Lead to the Prolonged TIR in Children With Type 1 Diabetes?","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2021-03-01","conditions":"Diabetes type1, Diabetes Mellitus, Type 1","enrollment":77},{"nctId":"NCT04233203","phase":"","title":"Faster Aspart on Insulin-pump Treated T1DM Patients","status":"COMPLETED","sponsor":"Jesús Moreno Fernández","startDate":"2020-01-31","conditions":"Type 1 Diabetes","enrollment":48},{"nctId":"NCT04711382","phase":"","title":"The Use of Faster Acting Aspart in Type 1 Diabetes Patients","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2018-01-29","conditions":"Type 1 Diabetes, Insulin, Time in Range","enrollment":438},{"nctId":"NCT04414579","phase":"PHASE4","title":"The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus","status":"UNKNOWN","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2019-03-27","conditions":"Type 1 Diabetes Mellitus","enrollment":45},{"nctId":"NCT03977727","phase":"PHASE3","title":"FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump","status":"COMPLETED","sponsor":"Texas Diabetes & Endocrinology, P.A.","startDate":"2019-06-11","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT04055480","phase":"NA","title":"Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2019-08-10","conditions":"Type 1 Diabetes","enrollment":25},{"nctId":"NCT03723759","phase":"PHASE1","title":"A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-10-26","conditions":"Diabetes Mellitus, Type 1","enrollment":56},{"nctId":"NCT02825251","phase":"PHASE3","title":"Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-07-06","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":472},{"nctId":"NCT03565666","phase":"PHASE2, PHASE3","title":"The Insulin-Only Bionic Pancreas Bridging Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-07-09","conditions":"Type1 Diabetes Mellitus","enrollment":36},{"nctId":"NCT03407599","phase":"PHASE1","title":"A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-01-08","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":46},{"nctId":"NCT02500706","phase":"PHASE3","title":"Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":1108},{"nctId":"NCT01831765","phase":"PHASE3","title":"Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-08-26","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":1290},{"nctId":"NCT01850615","phase":"PHASE3","title":"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-23","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":323},{"nctId":"NCT02670915","phase":"PHASE3","title":"Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":834},{"nctId":"NCT02933853","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-10-14","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":61},{"nctId":"NCT03215498","phase":"PHASE1","title":"A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-07-03","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":58},{"nctId":"NCT01819129","phase":"PHASE3","title":"Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":881},{"nctId":"NCT01618188","phase":"PHASE1","title":"A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-06-11","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":52},{"nctId":"NCT01934712","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-08-30","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":50},{"nctId":"NCT02003677","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-11-29","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":67},{"nctId":"NCT02568280","phase":"PHASE1","title":"Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-10-06","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":42},{"nctId":"NCT01774565","phase":"NA","title":"Closed-loop Insulin Delivery in the General Ward","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2016-08","conditions":"Diabetes Mellitus","enrollment":43},{"nctId":"NCT03335501","phase":"PHASE2","title":"Comparison of the Efficacy of Rapid-acting Aspart and Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-04-01","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT03212950","phase":"NA","title":"Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Ljubljana, Faculty of Medicine","startDate":"2017-07-10","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT01999322","phase":"PHASE3","title":"A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-11-19","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":37},{"nctId":"NCT02035371","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-01-13","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":41},{"nctId":"NCT02089451","phase":"PHASE1","title":"A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-03-17","conditions":"Diabetes, Healthy","enrollment":21},{"nctId":"NCT01121276","phase":"PHASE1","title":"A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-04","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":82},{"nctId":"NCT02033239","phase":"PHASE1","title":"A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":46},{"nctId":"NCT02131246","phase":"PHASE1","title":"A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-05","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":33},{"nctId":"NCT01924637","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-08","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":36},{"nctId":"NCT01682902","phase":"PHASE1","title":"A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-09","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":43},{"nctId":"NCT01992588","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-11","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT01469143","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-11","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":40},{"nctId":"NCT01296438","phase":"PHASE1","title":"A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-02","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Faster aspart","genericName":"Faster aspart","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Faster aspart is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}